Immunization with HBsAg-Fc fusion protein induces a predominant production of Th1 cytokines and reduces HBsAg level in transgenic mice

Chinese Medical Journal

Volumn 125, Issue 18, 2012, Pages 3266-3272

  Meng, Zhe feng ^a   Wang, Hua jing ^a   Yao, Xin ^a   Wang, Xuan yi ^b   Wen, Yu mei ^a   Dai, Jian xin ^b   Xie, You hua ^a   Xu, Jian qing ^a  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Fc receptor; Hepatitis B surface antigen transgenic mice; Hepatitis B virus; Therapeutic vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALUMINUM HYDROXIDE; ASPARTATE AMINOTRANSFERASE; FLT3 LIGAND; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOASSAY; IMMUNOHISTOCHEMISRTY; LIVER CELL; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; TH1 CELL; TRANSGENIC MOUSE;

ANIMALS; CHEMOKINE CCL2; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B SURFACE ANTIGENS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866699199     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.18.013     Document Type: Article

References (30)

1. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21.
2. Chen CC, Yen CH, Wu WY, Hu SW, Chen SC, Bell WR, et al. Epidemiology of hepatitis B virus infection among young adults in Taiwan, China after public vaccination program. Chin Med J 2007; 120: 1155-1158.
3. Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 2010; 17: 115-122.
4. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008; 15: 137-145.
5. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
6. Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 2010; 52: 616-619.
7. Wang HY, Chien MH, Huang HP, Chang HC, Wu CC, Chen PJ, et al. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol 2010; 84: 3454-3463.
8. Zhou YH, Wu C, Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J 2009; 122: 98-102.
9. Michel ML, Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005; Suppl 1: s108-s114.
10. Bockhold K, Riely CA, Jeffreys C. Overcoming obstacles to immunization in patients with chronic liver disease. Am J Med 2005; 118 Suppl 10A: s40-s45.
11. Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008; 3: e2565.
12. Wen YM, Qu D, Zhou SH. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Int Rev Immunol 1999; 8: 251-258.
13. Villinger F, Mayne AE, Bostik P, Mori K, Jensen PE, Ahmed R, et al. Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J Virol 2003; 77: 10-24.
14. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110: 71-79.
15. Wang H, Dai J, Hou S, Qian W, Li B, Ma J, et al. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy. Cancer Gene Ther 2005; 12: 769-777.
16. Pandey A, Bani S, Dutt P, Suri KA. Modulation of Th1/Th2 cytokines and inflammatory mediators by hydroxychavicol in adjuvant induced arthritic tissues. Cytokine 2010; 49: 114-121.
17. Kool M, Soullié T, van Nimwegen M, Willart MA, Muskens F, Jung S, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205: 869-882.
18. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008; 26: 2350-2359.
19. Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, et al. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol 2003; 71: 376-384.
20. Sette AD, Oseroff C, Sidney J, Alexander J, Chesnut RW, Kakimi K, et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. J Immunol 2001; 166: 1389-1397.
21. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Théry C, Rescigno M, et al. Fc gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189: 371-380.
22. Yada A, Ebihara S, Matsumura K, Endo S, Maeda T, Nakamura A, et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FccRIIB-and FccRI/III-mediated immune complex uptake. Cell Immunol 2003; 225: 21-32.
23. Fernández N, Renedo M, García-Rodríguez C, Sánchez Crespo M. Activation of monocytic cells through Fc gamma receptors induces the expression of macrophage-inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES. J Immunol 2002; 169: 3321-3328.
24. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962.
25. Pulendran B, Smith JL, Jenkins M, Schoenborn M, Maraskovsky E, Maliszewski CR. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J Exp Med 1998; 188: 2075-2082.
26. Zou Z, Li B, Xu D, Zhang Z, Zhao JM, Zhou G, et al. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. J Clin Gastroenterol 2009; 43: 182-190.
27. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19: 157-169.
28. Wirth S, Guidotti LG, Ando K, Schlicht HJ, Chisari FV. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. J Immunol 1995; 154: 2504-2515.
29. Chung PW, Suen SH, Chan OK, Lao TH, Leung TY. Awareness and knowledge of hepatitis B infection and prevention and the use of hepatitis B vaccination in the Hong Kong adult Chinese population. Chin Med J 2012; 125: 422-427.
30. Li LZ, Yang Y, Yuan SH, Wan YM, Qiu C, Feng YL, et al. Establishing a Th17 based mouse model for preclinical assessment of the toxicity of candidate microbicides. Chin Med J 2010; 123: 3381-3388.